Business
Carlsmed Reports Third Quarter 2025 Financial Results and Raises Full-Year Guidance
Third quarter revenue of $13.1 million, representing 98% growth YoY Raising full year 2025 revenue guidance to $49 million - $50 million CARLSBAD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the third quarter ended September 30, 2025. "We delivered another strong quarter with 98% revenue growth year-over-year, exp
About this update from Carlsmed, Inc.
[{"type":"image","alt":"Carlsmed","displaySize":"","headline":null,"caption":"Carlsmed","className":"","disableSlideshowImg":false,"size":{"original":{"width":282,"height":62,"url":"https://media.zenfs.com/en/globenewswire.com/cccd860298c64d0a18c1d7b3706250f7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hS_gs.MQTCoePNI_FWsiww--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/cccd860298c64d0a18c1d7b3706250f7","width":282,"height":62}},"lazy":false},{"type":"text","content":"Third quarter revenue of $13.1 million, representing 98% growth YoY","length":67,"tagName":"p"},{"type":"text","content":"Raising full year 2025 revenue guidance to $49 million - $50 million","length":68,"tagName":"p"},{"type":"text","content":"CARLSBAD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the third quarter ended September 30, 2025.","length":282,"tagName":"p"},{"type":"text","content":""We delivered another strong quarter with 98% revenue growth year-over-year, expanded gross margins to 76%, increased surgeon users by more than 70% year-over-year, and reduced lead times to within 8 business days. These achievements demonstrate the incredible momentum and speed at which we are scaling while maintaining operational excellence,” said Mike Cordonnier, Chairman and CEO of Carlsmed. “With NTAP reimbursement for cervical procedures secured and more than 50 patients treated in our clinical evaluation, we are tracking toward launching our cervical spine platform early next year to bring our transformative digital surgery approach to an even broader patient population.”","length":692,"tagName":"p"},{"type":"text","content":"Recent Business Highlights ","length":27,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Reduced lead time for our aprevo® interbody implants to hospitals to within eight business days of surgical plan approval beginning October (from 10 business days exiting Q2 2025 and 20 business days in Q3 2024)","length":211,"tagName":"p"}]},{"val":[{"type":"text","content":"CMS New Technology Add-On Payment (NTAP) went into effect on October 1, 2025, for aprevo® cervical procedures; commercial launch is...